title: Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
abstract: A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.
authors.affiliation: University of Michigan, Ann Arbor.
authors.forename: S
authors.initials: S
authors.lastname: Urba
authors.forename: J
authors.initials: J
authors.lastname: Doroshow
authors.forename: C
authors.initials: C
authors.lastname: Cripps
authors.forename: F
authors.initials: F
authors.lastname: Robert
authors.forename: E
authors.initials: E
authors.lastname: Velez-Garcia
authors.forename: B
authors.initials: B
authors.lastname: Dallaire
authors.forename: D
authors.initials: D
authors.lastname: Adams
authors.forename: R
authors.initials: R
authors.lastname: Carlson
authors.forename: A
authors.initials: A
authors.lastname: Grillo-Lopez
authors.forename: J
authors.initials: J
authors.lastname: Gyves
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011798:Quinaldines
chemical_list: D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; C046943:brequinar; D011798:Quinaldines